GEMS stands for ” Genome-wide Epistasis for cardiovascular severity in Marfan Study “.
The aim of GEMS is to identify protective modifier genes (= epistatic genes) within the whole human genome capable of explaining the variability of cardiovascular damage found in people with Marfan syndrome. Such a discovery would open up new therapeutic avenues that would replicate the protective effects identified to prevent cardiovascular accidents.
This research is at the heart of the 101 Genomes Foundation. It is led by Professor Bart Loeys and the entire scientific committee of the 101 Marfan Genomes Project.
At the ABSM 20th Anniversary Gala, Professor Bart Loeys presented the GEMS project during his speech entitled
“ GEMS-An overview of current research…”
. This presentation and its support are available on the F101G website.
Ludivine and Romain
20191005 04 LOEYS Final_Loeys_Marfan ABSM
[embedyt] https://www.youtube.com/watch?v=zRHdEEitiQI[/embedyt]
